Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 1:04 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 5,323 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Continuous Dose Clear all
Completed Phase 1Phase 2 Interventional

Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.

NCT04409132
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Triferic
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Nov 3, 2026, 1:04 PM EST
Recruiting No phase listed Observational

Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.

NCT06252493
View directory record Official record
Conditions
Crohn Disease
Interventions
Radiotracer Injection, Contrast Media, Magnetic Resonance, Blood Draw, Glucagon, Imaging, Oral contrast media application
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Nov 3, 2026, 1:04 PM EST
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction

NCT04210180
View directory record Official record
Conditions
Smoking Cessation, Harm Reduction
Interventions
Varenicline, e-cigarette
Drug · Other
Lead sponsor
Rose Research Center, LLC
Industry
Eligibility
21 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Charlotte, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Nov 3, 2026, 1:04 PM EST
Completed Phase 3 Interventional

Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia

NCT00085124
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
oblimersen sodium, cytarabine, daunorubicin hydrochloride, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Chicago, Illinois • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 3, 2026, 1:04 PM EST
Completed Phase 2 Interventional Results available

A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease

NCT02577523
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ND0612 (Levodopa/Carbidopa solution), ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD
Drug
Lead sponsor
NeuroDerm Ltd.
Industry
Eligibility
30 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Chicago, Illinois • Farmington Hills, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Nov 3, 2026, 1:04 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pain Control in Colorectal Surgery: Liposomal Bupivacaine Block Versus Intravenous Lidociane

NCT04005859
View directory record Official record
Conditions
Colorectal Disorders
Interventions
Exparel, IV Lidocaine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Nov 3, 2026, 1:04 PM EST
Completed Phase 2 Interventional Results available

Study of Ataluren in Participants With Nonsense Mutation Aniridia

NCT02647359
View directory record Official record
Conditions
Aniridia
Interventions
Ataluren, Placebo
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
2 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Portland, Oregon • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Nov 3, 2026, 1:04 PM EST
Completed Not applicable Interventional Results available

Pain Management for Pectus Excavatum Repair

NCT00413582
View directory record Official record
Conditions
Postoperative Pain
Interventions
Epidural Analgesia, Patient-Controlled IV Analgesia
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 18 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 16, 2012 · Synced Nov 3, 2026, 1:04 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

NCT02923531
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
X4P-001, Nivolumab
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Nov 3, 2026, 1:04 PM EST
Completed Not applicable Interventional

MINDFUL-OBOT: Effect of Mindfulness on Opioid Use and Anxiety During Primary Care Buprenorphine Treatment

NCT03798431
View directory record Official record
Conditions
Opioid-use Disorder, Anxiety, Depression, Stress Related Disorder
Interventions
M-ROCC
Behavioral
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Nov 3, 2026, 1:04 PM EST
Completed Phase 2 Interventional Results available

AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts

NCT00396331
View directory record Official record
Conditions
Autologous Stem Cell Transplantation
Interventions
G-CSF plus plerixafor
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 78 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
8
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Nov 3, 2026, 1:04 PM EST
Terminated Phase 2 Interventional Results available

High-Dose Deferoxamine in Intracerebral Hemorrhage

NCT01662895
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Deferoxamine, Normal saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Palo Alto, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Nov 3, 2026, 1:04 PM EST
Completed Phase 1 Interventional

Study of AMV564 in Patients With AML

NCT03144245
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
AMV564, AMV564 in combination with pembrolizumab
Biological · Combination Product
Lead sponsor
Amphivena Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
10
States / cities
San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Nov 3, 2026, 1:04 PM EST
Completed Phase 2 Interventional Results available

Single-agent Cobimetinib for Adults With Histiocytic Disorders

NCT02649972
View directory record Official record
Conditions
Histiocytic Disorders
Interventions
Cobimetinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Nov 3, 2026, 1:04 PM EST
Recruiting Phase 1 Interventional

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

NCT06889493
View directory record Official record
Conditions
Neuroendocrine Carcinoma, Neuroendocrine Tumors
Interventions
Seneca Valley Virus-001 (SVV-001), Nivolumab, Ipilimumab
Biological · Drug
Lead sponsor
Peter Hosein, MD
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Nov 3, 2026, 1:04 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study

NCT03143816
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Technosphere insulin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Nov 3, 2026, 1:04 PM EST
Completed Not applicable Interventional

Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring

NCT02596204
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Weekly Review, FitBit
Other · Device
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
8 Years to 17 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Nov 3, 2026, 1:04 PM EST
Completed Phase 2 Interventional Results available

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

NCT03556904
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ablative Radiation Therapy, Hormone therapy or chemotherapy
Radiation · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Nov 3, 2026, 1:04 PM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)

NCT00071487
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Placebo, Belimumab 1 mg/kg, Belimumab 4 mg/kg, Belimumab 10 mg/kg
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
60
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Nov 3, 2026, 1:04 PM EST
Completed Phase 1Phase 2 Interventional

Citrulline for Children Undergoing Cardiopulmonary Bypass Surgery

NCT00201214
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Heart Defects, Congenital
Interventions
Citrulline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
Up to 18 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Nov 3, 2026, 1:04 PM EST
Not listed Phase 4 Interventional Accepts healthy volunteers

Optimal Effective Local Anesthetic Volume for Pain Relief Using Brachial Plexus Block

NCT05868993
View directory record Official record
Conditions
Post Operative Pain
Interventions
Dose of 0.5% Ropivacaine
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Nov 3, 2026, 1:04 PM EST
Terminated Phase 3 Interventional Results available

A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

NCT03495921
View directory record Official record
Conditions
Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms
Interventions
Vigil, Irinotecan, Temozolomide
Biological · Drug
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Little Rock, Arkansas • Los Angeles, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Nov 3, 2026, 1:04 PM EST
Completed Phase 1Phase 2 Interventional

Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment

NCT02603614
View directory record Official record
Conditions
Heart Failure, Renal Insufficiency
Interventions
Cenderitide, Placebo
Drug
Lead sponsor
Capricor Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Nov 3, 2026, 1:04 PM EST
Completed Phase 1 Interventional

Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212

NCT01387204
View directory record Official record
Conditions
Cancer
Interventions
GSK1120212
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Nov 3, 2026, 1:04 PM EST